|
KMID : 0370220210650030169
|
|
Yakhak Hoeji
2021 Volume.65 No. 3 p.169 ~ p.173
|
|
|
FDA Approved Radiopharmaceuticals in 2020
|
|
Lim Tae-Hyeong
Ha Hyun-Soo
Byun Young-Joo
|
|
|
Abstract
|
|
|
|
Radiopharmaceuticals are radioactive isotopes and labeled compounds used to diagnose and treat diseases. The globalradiopharmaceutical market is expected to grow at an average annual rate of 12.4%, reaching $14,728 million by 2023. Four ofthe 53 new drugs approved by the US FDA in 2020 are radiopharmaceuticals. All four radiopharmaceuticals are radioisotopelabeleddiagnostics used in positron emission tomography (PET) imaging. This review describes four FDA-approvedradiopharmaceuticals, including incorporated radioisotopes, target proteins, modes of action, and clinical indications.
|
|
|
KEYWORD
|
|
|
radiopharmaceuticals, PET imaging, diagnostics
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|